| 项琳.甲泼尼龙联合Vit D3治疗复发型多发性硬化的临床研究项琳[J].浙江中西医结合杂志,2016,26(6): |
| 甲泼尼龙联合Vit D3治疗复发型多发性硬化的临床研究项琳 |
| Clinical studies of methylprednisolone therapy combined with Vit D3 for Relapsing multiple sclerosis |
| 投稿时间：2015-08-01 修订日期：2015-11-06 |
| DOI： |
| 中文关键词: 多发性硬化 甲泼尼龙 维生素D3 |
| 英文关键词:multiple sclerosis methylprednisolone vitamin D3 |
| 基金项目: |
|
| 摘要点击次数: 1046 |
| 全文下载次数: 8 |
| 中文摘要: |
| 【】目的：研究甲泼尼龙联合Vit D3(维生素D3)治疗复发型多发性硬化的有效性和安全性。方法：筛选我科自2012年1月至2013年6月收治的复发型多发性硬化患者56例并随机分组,基础组患者急性期用甲泼尼龙冲击治疗,缓解期六个月内口服甲泼尼龙,联合组用药患者急性期同样用甲泼尼龙冲击治疗,缓解期六个月内口服甲泼尼龙及Vit D3,随访期2年间仅服用Vit D3,评估复发次数及间隔时间、EDSS评分等临床疗效指标及不良反应。结果：治疗前,两组患者的年龄、病程及复发次数等一般资料及治疗后多项指标组间比较差别无显著统计学意义(P≥0.05)。治疗后24m时,联合组增加1例脑神经受损患者显著少于基础组增加5例患者(P＜0.05)；治疗后24m,联合组患者多发性硬化复发的次数(1.13±0.52)、复发时间间隔(248.13±35.05)、EDSS值(3.32±0.67)均优于基础组患者的复发次数(1.53±0.65)、复发时间间隔(329.21±32.65)、EDSS值(3.93±0.58)(P＜0.05或P＜0.01)。结论：甲泼尼龙联合Vit D3能够延迟多发性硬化再次发作的时间,减少发作次数,减慢硬化发展速度。 |
| 英文摘要: |
| Objective To research efficacy and safety of methylprednisolone combined with Vit D3 (vitamin D3) treatment for relapsing multiple sclerosis. Methods 56 relapsing multiple sclerosis patients treated in our department were screened from January 2012 to June 2013 and were randomly divided into two groups: 28 patients in the basis treatment group were treated with methylprednisolone in the acute phase and treated with methylprednisolone in oral in the remission phase. Treatment in the acute phase and remission phase last six months. 28 patients in the combined treatment group were treated Vit D3 in the two years in clouding methylprednisolone therapy was the same above. Relapse frequency and time interval, EDSS score and other clinical indicators of and adverse reactions were evaluated. Result No statistically significant results were obtained after comparison of general information such as age, duration, number of relapse, EDSS values between the two groups (P≥0.05) before the treatment and comparison of a number of indicators after the treatment (P≥0.05 ). In 24 months after treatment, one case of new patients with brain damage in the combination group was significantly less than five new cases of brain damage in patients basic group (P <0.05); After 24 months treatment, multiple sclerosis relapse frequency (1.13 ± 0.52), the recurrence interval (248.13 ± 35.05), EDSS value (3.32 ± 0.67) of patients in the combined group were better than multiple sclerosis relapse frequency (1.53 ± 0.65), recurrence interval (329.21 ± 32.65), EDSS value (3.93 ± 0.58) of patients in the basic group (P <0.05 or P <0.01). Conclusion Methylprednisolone joint Vit D3 can delay the onset of multiple sclerosis time, reduce the number of attacks, be slow down hardening rate of development. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
